Vif and Apobec3G in the innate immune response to HIV: a tale of two proteins (Q37119030)

18 August 2017

1 reference

title

Vif and Apobec3G in the innate immune response to HIV: a tale of two proteins (English)

1 reference

18 August 2017

Melissa A Farrow

1

1 reference

PubMed ID

18366335

18 August 2017

Ann M Sheehy

series ordinal

2

1 reference

PubMed ID

18366335

18 August 2017

language of work or name

1 reference

1 April 2008

1 reference

18 August 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

18 August 2017

3

1 reference

18 August 2017

2

1 reference

18 August 2017

145-154

1 reference

The HIV 'A' (sor) gene product is essential for virus infectivity

18 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

The sor gene of HIV-1 is required for efficient virus transmission in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Evidence for a newly discovered cellular anti-HIV-1 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Hypermutation of HIV-1 DNA in the Absence of the Vif Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

DNA deamination mediates innate immunity to retroviral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Molecular mechanisms of antibody somatic hypermutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Constitutive expression of AID leads to tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Cytidine deamination of retroviral DNA by diverse APOBEC proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Antiviral potency of APOBEC proteins does not correlate with cytidine deamination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

APOBEC-mediated viral restriction: not simply editing?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

The interaction between HIV-1 Gag and APOBEC3G.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

APOBEC3G incorporation into human immunodeficiency virus type 1 particles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Selection forces and constraints on retroviral sequence variation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

APOBEC3G levels predict rates of progression to AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Derepression of microRNA-mediated protein translation inhibition by apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G) and its family members

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

Apolipoprotein B mRNA–Editing Enzyme, Catalytic Polypeptide–Like 3G: A Possible Role in the Resistance to HIV of HIV‐Exposed Seronegative Individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

The CD16+ Monocyte Subset Is More Permissive to Infection and Preferentially Harbors HIV-1 In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.2.145

21 January 2018

Identifiers

DOI

10.2217/17460913.3.2.145

1 reference

18 August 2017

1 reference

PubMed ID

18366335